Neuromuscular Disorders

In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression

In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression

By

The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.

Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis

Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis

By

Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.

Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia

Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia

By

Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.

In Multiple Sclerosis, Hand Strength May Indicate Disease Status

In Multiple Sclerosis, Hand Strength May Indicate Disease Status

By

In patients with MS, hand function often correlates with measures of quality of life.

Multiple Sclerosis May Have Causal Link to Osteoporosis

Multiple Sclerosis May Have Causal Link to Osteoporosis

By

The prevalence of osteoporosis was greater in patients with MS than in matched controls.

In MS, Anxiety, Cognitive Fatigue May Affect Visual Memory

In MS, Anxiety, Cognitive Fatigue May Affect Visual Memory

By

Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.

Multiple Sclerosis Relapse Rate Linked to Puberty in Boys

Multiple Sclerosis Relapse Rate Linked to Puberty in Boys

By

Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.

New Amyotrophic Lateral Sclerosis Tx Approved by FDA

New Amyotrophic Lateral Sclerosis Tx Approved by FDA

Radicava is the first approved treatment for ALS in over 20 years.

ALS Prognosis Better Predicted With Addition of MRI Measures

ALS Prognosis Better Predicted With Addition of MRI Measures

By

More accurate prediction of ALS prognosis can allow for better planned palliative care.

Vitamin D Deficiency Affects Cognition in Multiple Sclerosis

Vitamin D Deficiency Affects Cognition in Multiple Sclerosis

By

Longer studies are needed to further evaluate the effect of vitamin D supplementation on cognition in multiple sclerosis.

Pediatric Multiple Sclerosis Linked to Epstein-Barr, Herpes Simplex Virus Exposure

Pediatric Multiple Sclerosis Linked to Epstein-Barr, Herpes Simplex Virus Exposure

By

Increased risk of pediatric multiple sclerosis was observed in patients with prior exposure to EBV, HSV-1, and vitamin D deficiency.

In Relapsing MS, Fatigue, Limb Problems May Signal Risk for Disease Conversion

In Relapsing MS, Fatigue, Limb Problems May Signal Risk for Disease Conversion

By

In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

By

More participants achieved clinical NEDA with DMF than placebo over 2 years in the integrated analysis.

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

By

The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.

In Multiple Sclerosis, Anxiety May Signal Depression

In Multiple Sclerosis, Anxiety May Signal Depression

By

A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.

Meditation May Benefit Anxiety, Depression in Amyotrophic Lateral Sclerosis

Meditation May Benefit Anxiety, Depression in Amyotrophic Lateral Sclerosis

By

Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.

RENEW Trial: Promising Results for Optic Neuritis Treatment

RENEW Trial: Promising Results for Optic Neuritis Treatment

By

Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.

FDA Approves Duchenne Muscular Dystrophy Drug

FDA Approves Duchenne Muscular Dystrophy Drug

By

Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

By

Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

By

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

MicroRNA in Multiple Sclerosis May Signify Disease Progression

MicroRNA in Multiple Sclerosis May Signify Disease Progression

By

Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

By

Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

By

Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

By

Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.

Alexion Seeking New Indication for Myasthenia Gravis Drug

Alexion Seeking New Indication for Myasthenia Gravis Drug

By

Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Template Improves Quality of Report on MRI for Multiple Sclerosis

Template Improves Quality of Report on MRI for Multiple Sclerosis

By

More structured MRI reports may aid in the diagnosis of multiple sclerosis.

Potential Prognostic Biomarker for Clinically Isolated Syndrome

Potential Prognostic Biomarker for Clinically Isolated Syndrome

By

It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.

FDA Approves First Treatment for Spinal Muscular Atrophy

FDA Approves First Treatment for Spinal Muscular Atrophy

By

The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.

ACE Inhibitors May Help Slow Myocardial Fibrosis In Muscular Dystrophy

ACE Inhibitors May Help Slow Myocardial Fibrosis In Muscular Dystrophy

By

Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.

Low Neonatal Vitamin D May Increase Risk of MS

Low Neonatal Vitamin D May Increase Risk of MS

By

Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.

Sign Up for Free e-newsletters